Gaillard, S., Gay, L. M., Steiner, M., Andreano, K., Davidson, B. A., Havrilesky, L. J., … Elvin, J. A. (2018). Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies. In Journal of Clinical Oncology (Vol. 36, pp. 5590–5590). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.5590

Gaillard, Stephanie, Laurie M. Gay, Meghan Steiner, Kaitlyn Andreano, Brittany Anne Davidson, Laura Jean Havrilesky, Angeles Alvarez Secord, et al. “Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies.” In Journal of Clinical Oncology, 36:5590–5590. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5590.

Gaillard S, Gay LM, Steiner M, Andreano K, Davidson BA, Havrilesky LJ, et al. Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5590–5590.

Gaillard, Stephanie, et al. “Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 5590–5590. Crossref, doi:10.1200/jco.2018.36.15_suppl.5590.

Gaillard S, Gay LM, Steiner M, Andreano K, Davidson BA, Havrilesky LJ, Secord AA, Valea FA, Colon-Otero G, Zajchowski DA, Chang C-Y, McDonnell DP, Berchuck A, Elvin JA. Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5590–5590.